| Literature DB >> 28785577 |
Fahmi Yousef Khan1, Mohammed Abu-Khattab2, Eman Abdulrahman Almaslamani3, Abubaker Ahmed Hassan2, Shehab Fareed Mohamed4, Abdurrahman Ali Elbuzdi5, Nada Yagoub Elmaki2, Deshmukh Anand6, Doiphode Sanjay6.
Abstract
BACKGROUND AND OBJECTIVES: Bacterial meningitis is a common medical condition in Qatar. The aim of this study was to describe the clinical characteristics of bacterial meningitis, the frequency of each pathogen, and its sensitivity to antibiotics and risk factors for death. PATIENTS AND METHODS: This retrospective study was conducted at Hamad General Hospital between January 1, 2009, and December 31, 2013.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28785577 PMCID: PMC5530415 DOI: 10.1155/2017/2975610
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Demographic and clinical data of the 117 patients involved in this study.
| Variable | Number (%), mean ± SD (range) |
|---|---|
|
| |
| M | 81 (69.2) |
| F | 29 (30.8) |
|
| 26.4 ± 22.3 (2–74) |
|
| |
| <1 | 26 (22.2) |
| 1–5 | 11 (9.4) |
| 6–14 | 6 (5.1) |
| 15–24 | 12 (10.3) |
| 25–34 | 13 (11.1) |
| 35–44 | 17 (14.5) |
| 45–54 | 23 (19.7) |
| 55–64 | 6 (5.1) |
| ≥65 | 3 (2.6) |
|
| |
| Qatari | 28 (23.9) |
| Non-Qatari | 82 (76.1) |
|
| |
| Diabetes mellitus | 9 (7.7) |
| Hypertension | 26 (22.2) |
| Head injury | 6 (5.1) |
| Neurosurgery | 54 (46.2) |
| Alcoholic | 4 (3.4) |
| Prematurity | 7 (6.0) |
| Liver cirrhosis | 1 (0.9) |
| Otitis media | 5 (4.3) |
| Malignancy | 8 (6.8) |
| Immunosuppression | 2 (1.7) |
|
| |
| Fever | 110 (94) |
| Mental alteration | 55 (47) |
| Headache | 43 (36.8) |
| Vomiting | 35 (29.9) |
| Meningism | 31 (26.5) |
| Seizures | 23 (19.7) |
| Bulging fontanel | 16 (13.7) |
| Hypotension (BP < 90/60 mmHg) | 12 (10.2) |
| Focal signs | 11 (9.4) |
| Photophobia | 7 (6.0) |
| Behavioral changes | 3 (2.6) |
| Petechial rash | 3 (2.6) |
|
| |
| Hydrocephalus | 19 (16.2) |
| Ischemic stroke | 5 (4.3) |
| Brain abscess | 4 (3.4) |
| Subdural empyema | 1 (0.9) |
| Adrenal insufficiency | 1 (0.9) |
| Vasculitis | 1 (0.9) |
Clinical data of the 117 patients involved in this study.
| Variable | Number (%), mean ± SD (range) |
|---|---|
|
| |
| Community-acquired | 59 (50.4) |
| Nosocomial | 58 (49.6) |
|
| |
| Cells/ | 3880.4 ± 8654.6 (20–66000) |
| Neutrophils% | 74.1 ± 26.1 (1–99) |
| Lymphocytes% | 22.9 ± 24.8 (1–98) |
| Protein (g/dL) | 222.8 ± 205.9 (38–936) |
| Glucose (mmol/L) | 2.1 ± 1.6 (0.1–6) |
| Positive Gram stain | 93 (79.5) |
| Positive culture | 112 (95.7) |
| Positive latex agglutination | 23 (19.7) |
|
| |
| Gram-positive | 62 (53) |
| Gram-negative | 55 (47) |
|
| 37 (31.6) |
|
| |
| Appropriate | 97 (82.9) |
| Inappropriate | 20 (17.1) |
|
| |
| Died | 14 (12.0) |
| Alive | 103 (88.0) |
Distribution of different isolates in relation to setting of acquisition of meningitis.
| Microorganism | Setting of acquisition | Total | |
|---|---|---|---|
| Nosocomial | Community-acquired | ||
| Gram-positive | |||
|
| 1 (100) | 0 | 1 |
|
| 5 (71.4) | 2 (28.6) | 7 |
|
| 1 (100) | 0 | 1 |
|
| 1 (100) | 0 | 1 |
|
| 1 (100) | 0 | 1 |
|
| 0 | 3 (100) | 3 |
|
| 0 | 1 (100) | 1 |
|
| 2 (100) | 0 | 2 |
|
| 14 (87.5) | 2 (12.5) | 16 |
|
| 2 (100) | 0 | 2 |
|
| 0 | 3 (100) | 3 |
|
| 0 | 1 (100) | 1 |
|
| 0 | 1 (100) | 1 |
|
| 0 | 1 (100) | 1 |
|
| 0 | 1 (100) | 1 |
|
| 0 | 19 (100) | 19 |
|
| 0 | 1 (100) | 1 |
| Gram-negative | |||
|
| 8 (100) | 0 | 8 |
|
| 2 (66.7) | 1 (33,3) | 3 |
|
| 0 | 1 (100) | 1 |
|
| 0 | 1 (100) | 1 |
|
| 0 | 1 (100) | 1 |
|
| 1 (100) | 0 | 1 |
|
| 3 (100) | 0 | 3 |
|
| 3 (75) | 1 (25) | 4 |
|
| 1 (50) | 1 (50) | 2 |
|
| 7 (58.3) | 5 (41.7) | 12 |
|
| 0 | 11 (100) | 11 |
|
| 5 (100) | 0 | 5 |
|
| 1 (100) | 0 | 1 |
|
| 0 | 1 (100) | 1 |
|
| 0 | 1 (100) | 1 |
| Total |
|
|
|
Distribution of microorganisms in relation to the age group.
| Microorganism | Age group | Total | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| <1 | 1–5 | 6–14 | 15–24 | 25–34 | 35–44 | 45–54 | 55–64 | ≥65 | ||
|
| 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 (0.8) |
|
| 0 | 0 | 0 | 0 | 0 | 2 | 3 | 2 | 1 | 8 (6.8) |
|
| 0 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 3 (2.6) |
|
| 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 (0.8) |
|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 (0.8) |
|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 (0.8) |
|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 (0.8) |
|
| 0 | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 0 | 3 (2.6) |
|
| 2 | 1 | 0 | 0 | 0 | 1 | 2 | 1 | 0 | 7 (5.9) |
|
| 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 (0.8) |
|
| 2 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 4 (3.4) |
|
| 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 (0.8) |
|
| 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 2 (1.6) |
|
| 2 | 0 | 0 | 2 | 1 | 1 | 4 | 2 | 0 | 12 (10.3) |
|
| 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 (0.8) |
|
| 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 (2.6) |
|
| 0 | 1 | 0 | 3 | 3 | 1 | 2 | 0 | 1 | 11 (9.4) |
|
| 0 | 0 | 1 | 0 | 2 | 1 | 1 | 0 | 0 | 5 (4.2) |
|
| 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 (0.8) |
|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 (0.8) |
|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 (0.8) |
|
| 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 (0.8) |
|
| 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 2 (1.6) |
|
| 6 | 2 | 0 | 2 | 1 | 3 | 1 | 1 | 0 | 16 (13.6) |
|
| 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 2 (1.6) |
|
| 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 (2.6) |
|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 (0.8) |
|
| 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 (0.8) |
|
| 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 (0.8) |
|
| 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 (0.8) |
|
| 3 | 2 | 3 | 2 | 3 | 2 | 4 | 0 | 0 | 19 (16.2) |
|
| 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 (0.8) |
|
| ||||||||||
| Total | 26 (22.2) | 11 (9.4) | 6 (5.1) | 12 (10.3) | 13 (11.1) | 17 (14.5) | 23 (19.7) | 6 (5.1) | 3 (2.6) | 117 (100) |
Antimicrobial resistance rate of Gram-positive CSF isolates.
| Microorganisms | TNP | pen | amp | oxc | eryt | clind | amclv | cotr | cfr | van | line | teic |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| 1 | 0 | 0 | NT | 0 | 0 | 0 | 0 | NT | 0 | NT | NT |
|
| 7 | NT | 0 | NT | NT | NT | NT | NT | NT | 0 | 0 | 0 |
|
| 1 | NT | 0 | NT | NT | NT | NT | NT | NT | 1 (100) | 0 | 0 |
|
| 1 | 0 | 0 | NT | NT | NT | NT | NT | 0 | 0 | NT | NT |
|
| 1 | 0 | 0 | NT | NT | 0 | 0 | NT | 1 (100) | 1 (100) | 0 | 0 |
|
| 3 | 0 | 0 | NT | NT | NT | NT | 0 | NT | NT | NT | NT |
|
| 1 | 1 (100) | 1 (100) | NT | 0 | 0 | 0 | 0 | NT | 0 | 0 | 0 |
| Coagulase-negative staphylococci | 20 | 20 (100) | 20 (100) | 19 (95) | 19 (95) | 10 (50) | 20 (100) | 9 (45) | NT | 0 | 0 | 0 |
|
| 8 | 1 (0.2) | 1 (0.2) | 0 | 1 (0.2) | 1 (0.2) | 0 | 1 (0.2) | 1 (0.2) | 0 | 0 | 0 |
|
| 19 | 6 (31.5) | 6 (31.5) | 6 (31.5) | 6 (31.5) | 6 (31.5) | 6 (31.5) | 3 (15.7) | 3 (15.7) | 0 | 0 | 0 |
TNP: total number of patients; pen: penicillin; amp: ampicillin; oxc: oxacillin; eryt: erythromycin; clind: clindamycin; amclv: amoxicillin/clavulanic acid; cotr: cotrimoxazole; cfr: ceftriaxone; van: vancomycin; line: linezolid; teic: teicoplanin; NT: not tested.
Antimicrobial resistance rate of Gram-negative cerebrospinal fluid isolates.
| Microorganisms | TNP | cfr | gen | fep | taz | cip | amclv | ctz | amk | mem | pen | rif | col | tig |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| 11 | 8 (72.7) | 8 (72.7) | 8 (72.7) | 8 (72.7) | 7 (63.6) | NT | 7 (63.6) | 7 (63.6) | 7 (63.6) | NT | NT | 0 | 0 |
|
| 1 | NT | NT | NT | NT | NT | NT | NT | NT | NT | NT | NT | NT | NT |
|
| 2 | 1 (50) | 2 (100) | 0 | 1 (50) | 0 | NT | 2 (100) | 2 (100) | 2 (100) | NT | NT | 2 (100) | 2 (100) |
|
| 4 | 3 (75) | 0 | 1 (25) | 3 (75) | 0 | 4 (100) | 3 (75) | 0 | 0 | NT | NT | NT | NT |
|
| 4 | 1 (25) | 1 (25) | 1 (25) | 0 | 1 (25) | 1 (25) | 1 (25) | 0 | 0 | NT | NT | NT | NT |
|
| 2 | 0 | NT | 0 | 0 | NT | 0 | NT | NT | NT | NT | NT | NT | NT |
|
| 12 | 3 (25) | 0 | 3 (25) | 2 (16.6) | 2 (16.6) | 7 (58.3) | 4 (33.3) | 0 | 0 | NT | NT | 0 | 0 |
|
| 8 | 0 | NT | 0 | 0 | 2 (25) | 0 | NT | NT | 0 | 0 | 2 (25) | NT | NT |
|
| 5 | NT | 0 | 0 | 0 | 0 | NT | 0 | 0 | 0 | NT | NT | 0 | 0 |
|
| 1 | NT | 0 | 0 | 0 | 0 | NT | 0 | 0 | 0 | NT | NT | 0 | 0 |
|
| 1 | 0 | 1 (100) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | NT | NT | NT | NT |
|
| 1 | 0 | 0 | 0 | 0 | 0 | 1 (100) | 0 | 0 | 0 | NT | NT | NT | NT |
TNP: total number of patients; cfr: ceftriaxone; gen: gentamicin; fep: cefepime; taz: piperacillin/tazobactam; cip: ciprofloxacin; amclv: amoxicillin/clavulanic acid; ctz: ceftazidime; amk: amikacin; mem: meropenem; pen: penicillin; rif: rifampicin; col: colistin; tig: tigecycline; NT: not tested.
Results of univariate analysis of in-hospital mortality predictors.
| Variable | Unadjusted odds ratio (95% CI) |
|
|---|---|---|
| Presence of underlying diseases | 2.4 (1.4–3.9) | 0.001 |
| Nosocomial infection | 3.2 (1.5–6.5) | 0.1 |
| Multidrug-resistant episodes | 4.7 (3.8–5.7) | 0.08 |
| Mental alteration | 4.9 (1.0–24.0) | 0.06 |
| Hypotension | 2.3 (0.7–7.3) | 0.003 |
| Inappropriate treatments | 1.9 (1.2–3.07) | 0.01 |
Results of multivariate analysis of in-hospital mortality independent factors.
| Variable | Adjusted odds ratio (95% CI) |
|
|---|---|---|
| Presence of underlying diseases | 1.8 (1.03–3.2) | 0.02 |
| Hypotension | 3.2 (1.4–7.3) | 0.04 |
| Inappropriate treatments | 1.7 (1.0–2.8) | 0.01 |